Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8, 33-38
eCollection

Rationale and Design of DUAL Study: Doxycycline to Upgrade Response in Light Chain (AL) Amyloidosis (DUAL): A Phase 2 Pilot Study of a Two-Pronged Approach of Prolonged Doxycycline With Plasma Cell-Directed Therapy in the Treatment of AL Amyloidosis

Affiliations

Rationale and Design of DUAL Study: Doxycycline to Upgrade Response in Light Chain (AL) Amyloidosis (DUAL): A Phase 2 Pilot Study of a Two-Pronged Approach of Prolonged Doxycycline With Plasma Cell-Directed Therapy in the Treatment of AL Amyloidosis

Anita D'Souza et al. Contemp Clin Trials Commun.

Abstract

Light chain (AL) amyloidosis is a plasma cell neoplasm associated with insoluble fibril deposition from clonal immunoglobulin chains systemically. The disease is associated with high early mortality and morbidity owing to advanced organ deposition as well as lack of proven de-fibrillogenic therapies. Pre-clinical and retrospective clinical data suggests that doxycycline has benefit in AL amyloidosis. The ongoing DUAL study is a single center, open label, phase 2 study in which patients with AL amyloidosis who are undergoing clone-directed therapy for the underlying neoplasm with oral doxycycline given for 1 year to test the hypothesis that prolonged doxycycline use will be safe, feasible, and lead to reduced early mortality in systemic AL amyloidosis and hasten organ amyloid response. Clinical follow up visits will occur at monthly intervals for systemic AL patients and at 3 monthly intervals for localized AL patients. Blood tests will be collected during these time points for hematologic response assessment. Organ testing will be conducted at 3 monthly intervals and radiologic testing will be conducted at 6 monthly intervals. Research blood samples will be collected at baseline, 6 and 12 months. Other correlative studies include matrix metalloproteinases (MMP), tissue inhibitor of metalloproteinases (TIMP) testing and patient-reported outcomes.

Keywords: Amyloidosis; Chemotherapy; Doxycycline; Light chain; Phase 2 clinical trial.

Figures

Fig. 1
Fig. 1
Pathophysiology and unmet needs in AL amyloidosis.

Similar articles

See all similar articles

Cited by 3 articles

  • Approach to a patient with cardiac amyloidosis.
    Strouse C, Briasoulis A, Fonseca R, Jethava Y. Strouse C, et al. J Geriatr Cardiol. 2019 Jul;16(7):567-574. doi: 10.11909/j.issn.1671-5411.2019.07.010. J Geriatr Cardiol. 2019. PMID: 31447895 Free PMC article. No abstract available.
  • Cardiac amyloidosis: the need for early diagnosis.
    Oerlemans MIFJ, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N. Oerlemans MIFJ, et al. Neth Heart J. 2019 Nov;27(11):525-536. doi: 10.1007/s12471-019-1299-1. Neth Heart J. 2019. PMID: 31359320 Free PMC article. Review.
  • Novel Approaches for the Management of AL Amyloidosis.
    Joseph NS, Kaufman JL. Joseph NS, et al. Curr Hematol Malig Rep. 2018 Jun;13(3):212-219. doi: 10.1007/s11899-018-0450-1. Curr Hematol Malig Rep. 2018. PMID: 29951831 Review.

References

    1. Sipe J.D., Benson M.D., Buxbaum J.N. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21:221–224. - PubMed
    1. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995;32:45–59. - PubMed
    1. D'Souza A., Dispenzieri A., Wirk B. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J. Clin. Oncol. 2015;33:3741–3749. - PMC - PubMed
    1. Dispenzieri A., Gertz M.A., Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012;26:137–154. - PubMed
    1. Kumar S.K., Gertz M.A., Lacy M.Q. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin. Proc. 2011;86:12–18. - PMC - PubMed
Feedback